Cochlear Ltd
ASX:COH

Watchlist Manager
Cochlear Ltd Logo
Cochlear Ltd
ASX:COH
Watchlist
Price: 250.58 AUD -2.41% Market Closed
Market Cap: 16.4B AUD

Cochlear Ltd
Total Other Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cochlear Ltd
Total Other Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Other Income CAGR 3Y CAGR 5Y CAGR 10Y
Cochlear Ltd
ASX:COH
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Somnomed Ltd
ASX:SOM
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Cyclopharm Ltd
ASX:CYC
Total Other Income
AU$669.7k
CAGR 3-Years
68%
CAGR 5-Years
N/A
CAGR 10-Years
52%
Optiscan Imaging Ltd
ASX:OIL
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Austco Healthcare Ltd
ASX:AHC
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
EMvision Medical Devices Ltd
ASX:EMV
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

Cochlear Ltd
Glance View

Economic Moat
Narrow
Market Cap
16.4B AUD
Industry
Health Care

Cochlear Ltd., the renowned medical device company, traces its roots back to the vibrant medical innovation scene of Australia in the 1980s. Born from the pioneering research of Professor Graeme Clark, who was driven by a personal mission to help the hearing-impaired, Cochlear embarked on a journey that redefined the possibilities for those living with hearing loss. Over the years, the company has evolved into a global leader in implantable hearing solutions, headlined by its flagship cochlear implants. These intricate devices bypass damaged portions of the ear, directly stimulating the auditory nerve to restore the sense of hearing, thus providing users with the ability to connect more profoundly with the world around them. As scientific research advanced, so did Cochlear, developing a range of complementary products tailored to different degrees and types of hearing impairment. In a business model built on innovation and patient support, Cochlear generates revenue by designing, manufacturing, and marketing a portfolio of hearing implant products and related services. The company's value proposition lies not only in the initial sale of these high-tech devices but also in the ongoing customer relationships through upgrades, accessories, and maintenance services. By investing significantly in research and development, Cochlear ensures continuous improvement and the introduction of new solutions that meet the evolving needs of patients and healthcare providers. Their ability to offer comprehensive post-implantation support, such as rehabilitation services and patient care programs, strengthens customer loyalty and establishes recurring revenue streams, enabling Cochlear to maintain its competitive edge in the global market.

COH Intrinsic Value
203.01 AUD
Overvaluation 19%
Intrinsic Value
Price

See Also

Back to Top